See more : Super Crop Safe Limited (SUCROSA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Cellivery Therapeutics, Inc. (268600.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cellivery Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Alcadon Group AB (publ) (ALCA.ST) Income Statement Analysis – Financial Results
- PT Sampoerna Agro Tbk (SGRO.JK) Income Statement Analysis – Financial Results
- Axfood AB (publ) (AXFOF) Income Statement Analysis – Financial Results
- Shivam Autotech Limited (SHIVAMAUTO.NS) Income Statement Analysis – Financial Results
- Old National Bancorp (ONB) Income Statement Analysis – Financial Results
Cellivery Therapeutics, Inc. (268600.KQ)
About Cellivery Therapeutics, Inc.
Cellivery Therapeutics, Inc. researches and develops therapeutic drugs for life-threatening lethal diseases, such as cancer, inflammation, metabolic, and neurodegenerative diseases. It develops small molecule, antibody, and vaccine drugs based on its Therapeutic molecule Systemic Delivery Technology. The company was founded in 2014 and is based in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 18.86B | 23.16B | 3.87B | 761.57M | 2.07B | 4.51B | 2.77B |
| Cost of Revenue | 22.64B | 26.09B | 4.25B | 2.00B | 3.55B | 3.02B | 1.98B |
| Gross Profit | -3.78B | -2.93B | -374.10M | -1.24B | -1.48B | 1.49B | 789.67M |
| Gross Profit Ratio | -20.02% | -12.64% | -9.66% | -162.52% | -71.19% | 32.97% | 28.47% |
| Research & Development | 6.95B | 20.81B | 8.61B | 6.44B | 5.37B | 410.27M | 223.14M |
| General & Administrative | 137.53M | 2.88B | 1.31B | 628.21M | 0.00 | 26.66M | 48.33M |
| Selling & Marketing | 5.47B | 22.31B | 2.77B | 849.51M | 0.00 | 652.11M | 364.42M |
| SG&A | 8.57B | 43.45B | 18.72B | 10.11B | 7.57B | 4.55B | 3.55B |
| Other Expenses | 0.00 | -272.64M | -346.95M | -186.20M | -162.69M | 0.00 | 0.00 |
| Operating Expenses | 19.30B | 64.54B | 27.68B | 16.74B | 13.11B | 6.54B | 13.46B |
| Cost & Expenses | 38.43B | 90.62B | 31.92B | 18.74B | 16.66B | 9.56B | 15.44B |
| Interest Income | 316.73M | 1.13B | 310.09M | 331.68M | 757.66M | 0.00 | 2.35B |
| Interest Expense | 5.19B | 6.44B | 2.66B | 764.94M | 7.00M | 1.60B | 2.41B |
| Depreciation & Amortization | 4.95B | 5.20B | 1.46B | 1.04B | 997.89M | 507.41M | 439.82M |
| EBITDA | -23.87B | -63.35B | -25.54B | -16.10B | -18.57B | -4.35B | -12.16B |
| EBITDA Ratio | -126.55% | -268.89% | -686.63% | -2,224.02% | -655.18% | -79.67% | -109.68% |
| Operating Income | -19.57B | -67.46B | -28.05B | -17.98B | -14.58B | -4.10B | -3.48B |
| Operating Income Ratio | -103.74% | -291.32% | -724.36% | -2,360.40% | -703.31% | -90.92% | -125.54% |
| Total Other Income/Expenses | -14.44B | -8.13B | -3.32B | -324.92M | -4.99B | -2.55B | -11.53B |
| Income Before Tax | -34.01B | -75.02B | -29.68B | -17.94B | -19.58B | -6.65B | -15.01B |
| Income Before Tax Ratio | -180.28% | -323.94% | -766.49% | -2,355.20% | -944.06% | -147.41% | -541.27% |
| Income Tax Expense | 29.01M | 140.70M | -1.61B | -688.22M | 73.00M | 46.97M | 5.41M |
| Net Income | -32.57B | -75.16B | -28.07B | -17.25B | -19.65B | -6.70B | -15.01B |
| Net Income Ratio | -172.67% | -324.54% | -724.84% | -2,264.83% | -947.58% | -148.45% | -541.08% |
| EPS | -889.35 | -2.98K | -833.92 | -535.26 | -632.25 | -325.00 | -1.36K |
| EPS Diluted | -889.35 | -2.98K | -833.92 | -535.26 | -632.25 | -325.00 | -1.36K |
| Weighted Avg Shares Out | 36.62M | 25.18M | 33.66M | 32.22M | 31.08M | 20.61M | 11.04M |
| Weighted Avg Shares Out (Dil) | 36.62M | 25.18M | 33.66M | 32.22M | 31.08M | 20.61M | 11.04M |
Source: https://incomestatements.info
Category: Stock Reports